MS FIRST - utilising a drug safety module for use in MS clinical practice to evaluate lymphocyte reduction in fingolimod treatment over time, demographic predictors of lymphopenia and association with reported safety events

J. Haartsen, S. Agland, J. Baker, T. Burke, L. Rath, J. Lechner-Scott, B. Taylor, S. Vucic, M. Barnett, M. Slee, S. Hodgkinson, O. Skibina, A. Kermode, E. Butler, N. Shuey, C. Shaw, T. Hardy, I. L. Tan, H. Butzkueven, T. Spelman

Research output: Contribution to journalAbstract/Meeting Abstractpeer-review

Original languageEnglish
Pages (from-to)18-19
JournalMultiple Sclerosis Journal
Volume21
Publication statusPublished - 2015

Cite this